Extended Data Fig. 7: Autogene cevumeran responders evidence lower post-vaccination serum CA19-9, equivalent chemotherapy doses and comparable intratumoural T cells.
From: Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
(A, B) Fraction of biomarker-evaluable patients with detectable CA19-9 (A) or circulating tumour DNA (ctDNA) (B) in the peripheral blood at diagnosis. Longitudinal serum CA19-9 levels in autogene cevumeran (vaccine) responders and non-responders (A, bottom). Circle = mean, error bars = standard error of the mean (C) Recurrence-free survival (RFS) stratified by atezolizumab response (left) and median primary tumour size (right). (D) Number of cycles of mFOLFIRINOX (chemotherapy) in vaccine responders and non-responders. (E) Intratumoural T cell infiltration in autogene cevumeran responders and non-responders. n = individual patients. P values by two-tailed Mann Whitney test (A), and log-rank test (C).
